

Radium Ra 223 dichloride (Xofigo®)

Place of Service
Office Administration
Outpatient Facility Infusion
Administration
Infusion Center Administration

HCPCS: A9606 therapeutic, per microcurie (mCi)

Condition listed in policy (*see criteria for details*)

- [Castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease](#)

AHFS therapeutic class: Radioactive agent

Mechanism of action: Alpha particle-emitting radioactive therapeutic agent

(1) Special Instructions and pertinent Information

Covered under the medical benefit, please submit clinical information for prior authorization review via fax.

(2) Prior Authorization/Medical Review is required for the following condition(s)

All requests for radium Ra 223 dichloride (Xofigo®) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

Castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease

1. Not being used in combination with chemotherapy

Covered Dose

Up to 55 kBq (1.49 microcurie) per kg IV every 4 weeks for a total of 6 injections

Coverage Period

One course (total of six doses) per lifetime

ICD-10:

C61

(3) The following condition(s) DO NOT require Prior Authorization/Preservice

All requests for radium Ra 223 dichloride (Xofigo®) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

(4) This Medication is NOT medically necessary for the following condition(s)

Coverage for a Non-FDA approved indication, requires that criteria outlined in Health and Safety Code § 1367.21, including objective evidence of efficacy and safety are met for the proposed indication.

Please refer to the Provider Manual and User Guide for more information.

(5) Additional Information

How supplied:

- Single-use vial at a concentration of 1,100 kBq/mL (30 microcurie/mL) at the reference date with a total radioactivity of 6,600 kBq/vial (178 microcurie/vial) at the reference date.

(6) References

- AHFS®. Available by subscription at <http://www.lexi.com>
- DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
- Xofigo® (radium Ra 223 dichloride) [Prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 12/2019.
- National Comprehensive Cancer Network. Prostate Cancer (Version 4.2022). Available at www.nccn.org

(7) Policy Update

Date of initial review: 3Q2023

Date of next review: 3Q2024

Changes from previous policy version:

- No clinical change to policy following routine annual review.

BSC Drug Coverage Criteria to Determine Medical Necessity

Reviewed by P&T Committee